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BCG appears to reduce acquisition of Mycobacterium tuberculosis (Mtb) infection in 44 
children, measured using interferon-gamma release assays (IGRAs). We explored whether 45 
BCG vaccination continues to be associated with decreased prevalence of Mtb infection in 46 
adults. 47 
Methods 48 
We conducted a cross-sectional analysis of data from adult contacts of tuberculosis cases 49 
participating in a UK cohort study. Vaccine effectiveness (VE) of BCG, ascertained based on 50 
presence of a scar or vaccination history, against latent tuberculosis infection (LTBI), 51 
measured via IGRA, was assessed using multivariable logistic regression. The effects of age 52 
at BCG and time since vaccination were also explored. 53 
Results 54 
Of 3453 recent tuberculosis contacts, 27.5% had LTBI. There was strong evidence of an 55 
association between BCG and LTBI (aOR=0.70, 95% CI 0.56-0.87, p=0.0017) yielding a VE 56 
of 30%. VE declined with time since vaccination, but there was evidence that LTBI 57 
prevalence was lower amongst vaccinated individuals even >20 years after vaccination, 58 
compared with non-vaccinated participants. 59 
Conclusion 60 
BCG is associated with lower prevalence of LTBI in adult contacts of tuberculosis. These 61 
results contribute to growing evidence that suggests BCG may protect against Mtb infection 62 
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as well as disease. This has implications for immunisation programmes, vaccine development 63 
and tuberculosis control efforts worldwide.  64 
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INTRODUCTION 67 
Tuberculosis (TB) is the leading cause of death from infectious disease worldwide.[1] The 68 
widely used Bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine against 69 
Mycobacterium tuberculosis (Mtb).[2] Infant BCG vaccination has shown consistently high 70 
efficacy of 70-80% against childhood TB, namely meningitis and miliary TB.[3] The 71 
protective effect of BCG against adult pulmonary disease varies geographically,[4–6] which 72 
may in part be associated with varying exposure to Mtb or environmental mycobacteria [7,8], 73 
which may mask or block protection induced by BCG.[4,9–11]  74 
Until recently it was not possible to determine if BCG vaccination prevents acquisition of 75 
Mtb infection or only limits progression from latent TB infection (LTBI) to active disease. 76 
This was due to limitations of the tuberculin skin test (TST), which can be positive following 77 
BCG vaccination and, to a lesser extent, exposure to environmental mycobacteria.[12,13] 78 
More recently developed interferon-gamma release assays (IGRAs) are more specific for Mtb 79 
infection,[14] as they measure interferon-gamma release from T-lymphocytes stimulated with 80 
antigens not present in BCG or most environmental mycobacteria.[15] Since the protective 81 
effect of BCG against Mtb infection was first demonstrated[16], several observational studies 82 
have investigated this phenomenon. A meta-analysis of 14 observational studies in children 83 
aged <16 years with recent exposure to active TB found a vaccine effectiveness (VE) of 19% 84 
against Mtb infection. In the six studies which followed up children who were IGRA-85 
positive, BCG was associated with a 58% reduction in the risk of active TB.[17]  86 
Data on whether this protection against Mtb infection continues into adulthood, as it appears 87 
to against disease,[18,19] are limited. Several observational studies of adults have found 88 
weak evidence of protection by BCG against infection measured via IGRA.[20–25] There has 89 
been no investigation of the influence of age at vaccination on VE of BCG against LTBI in 90 
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adults, or of changes in protection over time. These issues are important as, in order to assess 91 
the role of BCG (or similar vaccines in development) in TB control programmes, the effect of 92 
BCG on the full spectrum of TB should be understood.[26] In this cross-sectional study, we 93 
used baseline data from a large United Kingdom (UK) cohort study of adults at risk of Mtb 94 
infection to determine the presence and durability of BCG protection against Mtb infection, 95 
assessed by IGRA, and the potential factors that influence VE. 96 
METHODS 97 
Study design  98 
A cross-sectional study was carried out amongst participants recruited to the UK PREDICT 99 
study who were recent contacts of patients with active TB (‘contacts’). PREDICT was a 100 
prospective cohort study that aimed to assess the prognostic value of IGRAs in predicting the 101 
development of active TB among individuals with, or at risk of, LTBI, as previously 102 
described.[27] 10045 TB contacts, as well as recent migrants, aged ≥16 years were recruited 103 
between January 2011 and July 2015. Participants with evidence of active TB at baseline 104 
were excluded, and migrants were excluded from this analysis as it was unclear when their 105 
primary infection occurred. Contacts were recruited at contact tracing appointments for TB 106 
screening in TB clinics (part of the routine public health management of TB in the UK). 107 
After obtaining informed consent, study nurses completed a questionnaire with participants, 108 
including on demographic, social, medical and TB exposure history, took blood samples for 109 
IGRA testing, and administered a Mantoux TST (which was read 48-72 hours later).  110 
Most recruitment sites were in London, with one clinic each in Birmingham and Leicester. To 111 
increase the probability that any detected LTBI was due to recent infection, participants who 112 
reported previous contact with active TB (prior to that resulting in recruitment) were 113 
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excluded. Participants who reported a previous TB diagnosis were also excluded from this 114 
analysis, as a positive IGRA may reflect their prior TB disease rather than current LTBI. 115 
Primary exposure, outcome and covariates 116 
The primary exposure of interest was previous BCG vaccination. Vaccination status was 117 
determined by inspection of both arms for a vaccination scar by a trained study or TB nurse, 118 
combined with a vaccination history and documentation from a personally-held vaccination 119 
record (e.g. the ‘red book’) if available. A positive response was recorded when a scar was 120 
observed or there was documented evidence of BCG administration, and a negative response 121 
recorded if no scar was seen. If participants thought they had been vaccinated but no scar was 122 
observed, the interviewer recorded ‘unsure’ and this was treated as missing. Participants who 123 
had received vaccination were asked the year of vaccination. 124 
The outcome of interest was LTBI, measured via IGRA. LTBI was defined as a positive 125 
result on either or both of QuantiFERON-TB Gold In-Tube (QFT-GIT) and T-SPOT.TB. 126 
Those who were negative on both assays, or negative on one and indeterminate on the other, 127 
were considered not to have LTBI. Most participants had both IGRAs performed, however a 128 
small number were only tested with QFT-GIT, and LTBI was determined based on the single 129 
assay. If both assays were indeterminate, the outcome was considered missing. 130 
Self-reported questionnaire data included details of the TB exposure, country of birth, 131 
ethnicity (based on the Enhanced Tuberculosis Surveillance system categories[28]), smoking 132 
status (never or ever), social risk factors (none, or any of homelessness, imprisonment or use 133 
of controlled drugs), and medical details, including whether the participant had diabetes, HIV 134 
or other immunosuppression. 135 
Age at vaccination was calculated as the difference between vaccination and birth year, and 136 
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dichotomised based on the ages of vaccination recommended in typical BCG vaccination 137 
polices (≤2 years to reflect infant vaccination, >2 years for vaccination in childhood and at 138 
older ages). Time since vaccination was calculated as age at recruitment minus the stated age 139 
at vaccination, and grouped into three categories to avoid data sparsity (≤10 years, 11-20 140 
years, >20 years).[5] TB incidence in country of birth was obtained from WHO estimates for 141 
the year 2000.[29] Absolute latitude of country of birth, found to affect VE in previous 142 
studies[9], was calculated using average country latitude data from Google Public Data 143 
Explorer[30], and collapsed into 20° groups.[9,17]  144 
Statistical analysis 145 
To investigate the association between LTBI and BCG status (and all other covariates), cross-146 
tabulation, unadjusted ORs and likelihood ratio tests (LRTs) were calculated. For variables 147 
with no natural reference group, the largest group was used as the baseline. 148 
Multivariable analysis was performed using logistic regression and LRTs. Age group and sex 149 
were considered a priori confounders. Age group was treated as a categorical, rather than 150 
continuous, variable as this produced a better fit in bivariable analysis. Further confounding 151 
variables were included in the multivariable model based on the change-in-estimate method. 152 
All variables that were associated with BCG status or LTBI on bivariable analysis with p≤0.2 153 
(with none deemed to lie on the causal pathway) were added separately to the model. Any 154 
variable that resulted in a ≥10% relative change in the OR was kept in the model (with the 155 
variable that caused the largest change in the OR selected first if more than one variable 156 
caused a ≥10% change). All other variables were then individually re-added to the model 157 
until the addition of no further variables resulted in a 10% change in OR. All analyses used a 158 
‘complete-case’ approach. Vaccine effectiveness for LTBI was calculated as VE=1-OR. This 159 
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OR is the prevalence odds ratio[31], which approximates the incidence rate ratio in cross-160 
sectional studies.[32,33] 161 
The roles of age at vaccination and time since vaccination on the association between BCG 162 
and LTBI were then explored. Two further multivariable logistic regression models were 163 
fitted separately (for age at BCG and time since BCG), using the same modelling strategy as 164 
above. The analysis of age at BCG was stratified by place of birth (UK or non-UK). Due to 165 
collinearity between age at vaccination and time since vaccination, analysis of time since 166 
BCG was stratified by age at BCG (≤2 years or >2 years).  167 
Six sensitivity analyses of the primary multivariable model were performed: 1) with 168 
additional adjustment for smoking status and any social risk factor; 2) including adjustment 169 
for TB incidence of country of birth; 3) including only participants with concordant IGRAs; 170 
4) using binomial regression with a log-link to directly estimate the prevalence ratio (PR), 171 
which may not be well approximated by the OR as the outcome was common[34]; 5) 172 
restricting the analysis to household contacts of active TB cases, who likely had the most 173 
defined single TB exposure[35]; 6) including participants who reported earlier contact with 174 
people with active TB. We also performed additional analyses using TST results to measure 175 
LTBI. Two cut-off criteria were used to define positivity: firstly, TST≥5mm[36]; and 176 
secondly, TST ≥5mm in BCG-naïve, or ≥15mm in BCG-vaccinated participants (which 177 
better predicts disease progression[27]).  178 
To examine bias from missing data, observations with missing values were investigated for 179 
association with the outcome and exposure using cross-tabulation, together with 180 
multivariable analysis of factors associated with missing BCG status. 181 
Analysis was conducted using Stata v15.0. 182 
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RESULTS 183 
Participant inclusion 184 
Of 10045 participants enrolled in the PREDICT study, 9515 had no evidence of active TB 185 
and did not report a prior history of TB. 4310 participants were recent TB contacts, of whom 186 
857 had missing data on LTBI and/or BCG status, leaving 3453 participants in this cross-187 
sectional study (Figure 1). 188 
Baseline characteristics and bivariable analysis 189 
Of 3453 participants, 86.9% (3000/3453) had received BCG vaccination. The median age 190 
was 32 years (interquartile range 25-43) and 50.0% were male. 2420/3444 (70.3%) were born 191 
outside the UK (Table 1).  192 
The overall prevalence of LTBI was 27.5% (951/3453), 27.0% (809/3000) in those 193 
vaccinated and 31.4% (142/453) in the unvaccinated, yielding an unadjusted OR of 0.81 194 
(95% CI 0.65-1.00, p=0.054) (Table 1). Characteristics associated with increased LTBI 195 
prevalence on univariate analysis were male sex, older age, being born outside the UK, some 196 
ethnicities, lack of immunosuppression, having diabetes, lower latitudes of country of birth, 197 
TB incidence in country of birth, and household TB exposure. 198 
Multivariable analysis 199 
3399 (98.4%) participants were included in the complete-case analysis. Apart from sex and 200 
age (included a priori), latitude of country of birth was the key confounding variable, shifting 201 
the OR away from the null, and the only covariate retained in the final model. After adjusting 202 
for sex, age group and latitude of country of birth, there was strong evidence of an association 203 
 11 
between BCG and LTBI (OR 0.70, 95% CI 0.56-0.87, p=0.0017)(Table 2), thus the VE of 204 
BCG for LTBI in adult contacts of TB cases was 30% (95% CI 13-44%).  205 
Sensitivity analyses produced largely similar results (Appendix 1). Additional analyses using 206 
TST results found that BCG was positively associated with LTBI using a 5mm TST 207 
threshold, and negatively associated using a stratified threshold based on BCG status (OR 208 
0.50, 95% CI 0.40-0.63, p<0.001, Appendix 1). 209 
There was no evidence of an association between missing LTBI data and BCG vaccination 210 
(OR 1.05, 95% CI 0.74-1.49, p=0.79). However those without data on BCG status were more 211 
likely to have LTBI (OR 1.33, 95% CI 1.09-1.63)(Appendix 2). 212 
Vaccine effectiveness by age at vaccination and time since vaccination 213 
Data on reported age at (and time since) vaccination were available for 2195 (73%) of 3000 214 
BCG-vaccinated participants. Of the 641 people born in the UK, 497 (78%) were vaccinated 215 
aged >2 years. Of the 1554 people born outside the UK, 1268 (82%) were vaccinated aged ≤2 216 
years (Appendix 3). Protection against infection was observed following both infant and 217 
older age vaccination, among those born within and outside the UK, after adjusting for age 218 
group, sex and latitude of country of birth (Table 3). There was no clear pattern by age at 219 
vaccination, as the confidence intervals for the adjusted ORs overlapped.  220 
The association between BCG and LTBI, adjusted for age group, sex, ethnicity and country 221 
of birth, appeared to vary with time since vaccination in both age at vaccination strata (Table 222 
4). In those vaccinated at age 2 or younger, the protective association was greater in those 223 
vaccinated 11-20 years ago (OR 0.55 [95% CI 0.33-0.90]) than those vaccinated >20 years 224 
ago (OR 0.78 [0.60-1.00]). As this was an adult cohort, there were no participants vaccinated 225 
≤10 years ago in the group vaccinated in infancy. In participants vaccinated at age >2 years, 226 
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the protective association was greatest in those vaccinated ≤10 years ago (OR 0.31 [95% CI 227 
0.15-0.63]), versus those vaccinated 11-20 and >20 years ago (OR 0.73 [0.48-1.10] and 0.67 228 
[0.46-0.98] respectively). However there appeared to be evidence of protection more than 20 229 
years later in both those vaccinated in infancy and those vaccinated in childhood and older 230 
ages, compared to those without BCG vaccination. 231 
DISCUSSION 232 
Principal findings 233 
In this cross-sectional study, we found strong evidence of an association between BCG and 234 
LTBI in recent adult contacts of TB, with VE estimated as 30% (95% CI 13-44%). Protection 235 
against infection was seen following both infant and older age vaccination, among 236 
participants born within and outside the UK. The association appeared to differ by time since 237 
vaccination, in participants vaccinated at both ≤2 and >2 years of age. In those vaccinated 238 
aged ≤2 years, protection was seen in those vaccinated 11-20 years ago and, though less so, 239 
vaccinated >20 years ago. Among participants vaccinated at ages >2 years, the protective 240 
association was greater for those vaccinated <10 years ago than those vaccinated 10-20 years 241 
ago, where evidence of a protective effect was weak. In both groups, there remained evidence 242 
of some protection in participants vaccinated >20 years ago.  243 
Strengths and limitations 244 
To our knowledge, this is the largest adult study on the association between BCG and LTBI 245 
measured via IGRA in recent contacts of TB patients. The large sample size and rich dataset 246 
are key strengths. This enabled analysis by strata of age at BCG and time since vaccination 247 
and broad sensitivity analyses. Although the analysis of time since vaccination could not be 248 
adjusted for age at vaccination (and vice versa) due to collinearity, stratification helped 249 
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address this. Using both commercially-available IGRAs allowed a sensitivity analysis of 250 
those with concordant results, reducing the potential for outcome misclassification. 251 
There are some limitations in a cross-sectional study. The observational design cannot prove 252 
causality, and there may be confounding by other factors such as health-seeking behaviour. 253 
Furthermore, as many participants were born in high-burden countries, some may have been 254 
exposed to Mtb before vaccination. However, to increase the probability that vaccination 255 
preceded Mtb exposure, we only included recent TB contacts without prior reported TB 256 
exposure. Also, most participants born outside the UK were vaccinated in infancy, limiting 257 
exposure to Mtb before vaccination.  258 
Measurement error 259 
Similar to prior studies, this study relied predominantly on BCG scar to measure vaccination. 260 
BCG does not always result in scar formation, but may still confer protection in these 261 
cases.[35,37,38] Therefore some vaccinated participants may have been misclassified as non-262 
vaccinated, if there was no documented evidence otherwise. This would be non-differential 263 
with respect to IGRA, potentially biasing our VE estimates towards the null. Data on 264 
vaccination year was also likely subject to recall error, but again this is likely non-differential 265 
with regards to outcome.  266 
Most data on covariates was self-reported. Prevalence of HIV and smoking were relatively 267 
low, possibly reflecting social desirability biases. Residual confounding is also possible. For 268 
example, latitude of country of birth was an important confounder and may be a proxy 269 
measure of potential exposure to nontuberculous mycobacteria, as well as Mtb, but does not 270 
take into account the time lived at that latitude. Similarly, TB incidence in country of birth is 271 
an incomplete measure of Mtb exposure.  272 
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There is currently no gold standard for diagnosing LTBI, and a positive IGRA cannot 273 
distinguish between true ongoing latent Mtb infection with dormant yet viable bacteria and an 274 
immunological memory response following exposure to Mtb. Long-term follow-up studies 275 
(or development of a gold standard test for diagnosing LTBI) would help assess if IGRA does 276 
measure true infection preceding risk of disease. We found increased prevalence of TST 277 
reaction ≥5mm amongst vaccinated individuals, consistent with TST being affected by BCG. 278 
Stratified thresholds can improve the specificity of TST, as demonstrated by the protective 279 
association seen in our tiered 5/15mm analysis. However IGRAs are a more sensitive and 280 
specific surrogate marker for Mtb infection in BCG-vaccinated individuals.[14,15] 281 
Missing data 282 
Twenty percent of otherwise eligible participants were excluded due to missing data on LTBI 283 
and/or BCG. Missing data on LTBI were predominantly due to logistic factors (e.g. failed 284 
blood collection), so likely missing completely at random. This is supported by the lack of 285 
association between missing outcome data and BCG vaccination, and is therefore unlikely to 286 
be an important source of bias. 287 
BCG vaccination status was missing for 13% of participants, and these people were more 288 
likely to have LTBI. As it is harder to be certain of lack of vaccination, more unvaccinated 289 
participants may have been recorded as ‘unsure’ and therefore coded as missing (possibly 290 
leading to the association of missing BCG status with LTBI). However in these cases, when 291 
the missingness mechanisms are related to the exposure and covariates, but not the outcome, 292 
a logistic regression complete-case approach can still provide an unbiased estimate of the 293 
OR,[39] dependent on the model including the covariates with which missingness is related. 294 
While being non-UK born and of Pakistani ethnicity were associated with missing BCG 295 
status (and not included in the final model as they were not found to be important 296 
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confounders), these associations and numbers were small, so the overall bias of VE from 297 
missing BCG status is likely minimal. 298 
Comparison with existing literature 299 
The estimated VE of 30% is broadly consistent with other studies in adults.[20–25] Three 300 
studies in TB contacts had higher VEs than this study (ORs 0.11-0.5), though these were 301 
small studies restricted to close contacts and had wide confidence intervals that crossed 302 
1.[23–25] The lower VE in our analysis may reflect the limitations discussed above, which 303 
could have biased the estimate towards the null. 304 
Although the confidence intervals overlapped, our results suggest a possible decline in 305 
protection with increased time since vaccination. This concurs with studies of the duration of 306 
protection against active TB.[5,18] Our finding that protection against infection was seen 307 
following both infant and older age vaccination is less consistent with other studies reporting 308 
that protection against active TB is greater when vaccination occurs at younger ages, in 309 
immunologically naïve subjects.[5,9,40] Our findings are likely influenced by several factors. 310 
We do not have data on why participants were vaccinated at particular ages. However, those 311 
born outside the UK and vaccinated aged >2 years are likely to have been vaccinated after 312 
moving to the UK, where they would have been offered school-aged BCG vaccination only 313 
after negative TST results under the UK’s school-based BCG program, discontinued in 314 
2005.[41] Usually only infant vaccination programs are offered in high TB burden settings. 315 
In addition, infant vaccination is less likely to result in scar formation compared with 316 
vaccination at older ages.[42] Therefore non-differential misclassification is more likely in 317 
those vaccinated earlier, leading to an underestimate of VE in the younger age group. Finally, 318 
measurement of these variables was susceptible to bias, due to missing data and recall errors 319 
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for age at vaccination. These exploratory results should therefore be interpreted cautiously 320 
and confirmed in other studies, including with longitudinal design. 321 
Implications and future research 322 
This study suggests that BCG may protect against the acquisition of Mtb infection in adults 323 
and not only progression to disease.[17,26] This has implications for TB control strategies. 324 
The most recent WHO position paper on BCG reflects the growing evidence that BCG 325 
confers “a modest protective effect… against Mtb infection, representing a significant 326 
additional benefit of the BCG vaccine.”[43] Furthermore our data are consistent with 327 
evidence of durability of protection against disease,[18,19] which should be considered in 328 
cost-effectiveness and modelling studies by low-burden countries considering moving away 329 
from universal BCG vaccination to targeted vaccination of high-risk groups.[43]  330 
The effect that BCG may have on wider transmission dynamics is unclear, though 331 
preliminary modelling studies suggest a vaccine that protects against Mtb infection would 332 
have a high population-level impact on TB incidence, across a range of exposure 333 
intensities.[44] Future modelling studies of TB transmission and burden should therefore 334 
include sensitivity analyses that account for some degree of protection against infection.[43] 335 
Finally, these findings may contribute to understanding the mechanism of action of BCG. 336 
This is vital in the development and evaluation of new TB vaccines, since many vaccine 337 
candidates rely on a BCG-boosting strategy.[45] Novel vaccines must, and are starting to 338 
show they do, confer additional protection beyond the effect of BCG on both Mtb infection 339 
and disease progression.[46] Prevention of infection measured via IGRA is being examined 340 
as a shorter-term endpoint in efficacy trials of new TB vaccines, accelerating their 341 
assessment.[47] A recent trial of BCG revaccination versus vaccination with a novel subunit 342 
vaccine assessed vaccine efficacy using IGRA conversion as a measure of Mtb acquisition 343 
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and sustained IGRA positivity to reflect sustained infection.[48] Our study suggests BCG-344 
like vaccines that prevent infection may also provide long-term durability of protection. 345 
Our study contributes to the growing evidence that suggests BCG can act partially by 346 
providing protection against Mtb infection as well as disease. This has important implications 347 
for immunisation programmes, vaccine development and assessment, and TB control efforts 348 
worldwide.   349 
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TABLES AND FIGURES 360 
Figure 1: Recruitment of participants to the PREDICT study and inclusion in cross-sectional 361 
study.  362 
 363 
TB = tuberculosis; LTBI = latent tuberculosis infection; BCG = Bacillus Calmette-Guérin. 364 
* Contacts were defined as people with a cumulative duration of exposure to the index case 365 
(pulmonary or extra-pulmonary TB) of >8 hours in a confined space during the period of 366 
infectiousness. 367 
  368 
10045 enrolled participants 
9515 participants without known 
current/previous TB 
175 (1.7%) with active TB at baseline 
355 (3.5%) with previous TB diagnosis 
4310 recent TB contacts* included in 
cross-sectional study 
857 (19.9%) missing LTBI and/or BCG data 
(explored in Appendix 2) 
3453 participants with data available on 
LTBI and BCG status 
5205 (54.7%) not included in cross-sectional 
study, if a recent entrant (4558) and/or 
reported prior contact with TB (1140) 
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Table 1: Cross sectional study baseline characteristics and unadjusted ORs of their 369 
association with LTBI (n=3453). 370 






Crude OR 95% CI p value* 
BCG vaccination 
 
No 142/453 31.4 1  
0.054 Yes 809/3000 27.0 0.81 0.65-1.00 
Sex 
(missing [m]=16) 
Male 538/1726 31.2 1   
Female 410/1711 24.0 0.70 0.60-0.81 <0.001 
Age group, years 
(m=1) 
16-25 213/965 22.1 1  
<0.001 
26-35 328/1175 27.9 1.37 1.12-1.67 
36-45 195/601 32.5 1.70 1.35-2.13 
>45 215/711 30.2 1.53 0.24-0.33 
Country of birth 
(m=9) 
UK 155/1024 15.1 1  
<0.001 Non-UK 790/2420 32.6 2.72 2.25-3.29 
Ethnicity 
(m=76) 
Indian 292/967 30.2 1  
<0.001 
White 137/709 19.3 0.55 0.44-0.70 
Black African 190/536 35.5 1.27 1.01-1.59 
Mixed 145/474 30.6 1.02 0.80-1.29 
Pakistani 71/245 29.0 0.94 0.69-1.28 
Bangladeshi 22/142 15.5 0.43 0.26-0.68 
Black Caribbean 31/162 19.1 0.55 0.36-0.83 
Black Other / 
Chinese/Other 
35/142 27.3 0.76 0.50-1.13 
Any social risk factor No 897/3227 27.8 1  
0.20 Yes 54/226 23.9 0.82 0.59-1.12 
HIV 
(m=111) 
No 913/3317 27.5 1  
0.96 Yes 7/25 28.0 1.02 0.43-2.50 
Other immunosuppression 
(m=6) 
No 928/3338 27.8 1  
0.02 Yes 20/110 18.2 0.58 0.35-0.94 
Diabetes 
(m=6) 
No 869/3236 26.9 1  
0.0007 Yes 80/211 37.9 1.66 1.25-2.22 
Smoking status 
(m=16) 
Ever 207/822 25.2 1  
0.078 Never 741/2615 28.4 1.17 0.98-1.41 
Latitude of country of birth 
(m=37) 
<20° 265/779 34.0 1  
<0.001 
20-40° 455/1378 33.0 0.96 0.79-1.15 
>40° 221/1259 17.6 0.41 0.34-0.51 
TB incidence per 100 000 of 
country of birth (m=46) 
≤10 26/115 22.6 1  
<0.001 
11-40 200/1252 16.0 0.65 0.41-1.03 
41-100 36/129 28.0 1.33 0.74-2.37 
101-150 15/69 22.1 0.97 0.47-1.99 
151-300 584/1621 36.0 1.93 1.23-3.02 
≥300 77/222 34.7 1.82 1.08-3.05 
Setting of TB exposure 
(m=274) 
Household 671/2149 31.2 1  
<0.001 Non-household 204/1030 19.8 0.54 0.46-0.65 
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*Derived from likelihood ratio test 371 
OR = odds ratio; LTBI = latent tuberculosis infection; n = number; CI = confidence interval; 372 
m = missing; UK = United Kingdom; HIV = human immunodeficiency virus   373 
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Table 2: Adjusted ORs for the association of LTBI and BCG vaccination from a 374 
multivariable logistic regression model (n=3399). 375 
Variable Group Adjusted OR* 95% CI p value** 
BCG vaccination No 1  
0.0017 Yes 0.70 0.56-0.87 
Sex Male 1  
<0.001 Female 0.70 0.60-0.82 
Age group (years) 
 
16-25 1  
0.0016 
26-35 1.31 1.07-1.61 
36-45 1.55 1.23-1.97 
>45 1.38 1.10-1.74 
Latitude of country of birth 
 
<20° 1  
<0.001 
20-40° 0.92 0.76-1.12 
>40° 0.42 0.34-0.52 
*Adjusted for all other variables in the table 376 
**Likelihood ratio test p value 377 
OR = odds ratio; LTBI = latent tuberculosis infection; BCG = Bacillus Calmette-Guérin; n = 378 
number; CI = confidence interval.   379 
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Table 3: Crude and adjusted ORs for the association of LTBI and age at BCG vaccination, 380 
by place of birth.  381 
Birthplace Age at 
BCG 
Proportion with 
LTBI (%)  
Crude OR 
(95% CI) 






No BCG 32/151 (21.2) 1  1  
≤2 years 14/144 (9.7) 0.40 (0.20-0.79)  0.39 (0.19-0.77)  
>2 years 72/497 (14.5) 0.63 (0.40-1.00) 0.021 0.62 (0.38-1.00) 0.018 
Non-UK 
(n=1854) 
No BCG 110/300 (36.7) 1  1  
≤2 years 434/1268 (34.2) 0.90 (0.69-1.17)  0.83 (0.64-1.09)  
>2 years 83/286 (29.0) 0.71 (0.50-1.00)   0.123 0.63 (0.44-0.90) 0.040 
*Likelihood ratio test p value 382 
**Adjusted for age group, sex and latitude of country of birth. 383 
OR = odds ratio; LTBI = latent tuberculosis infection; UK = United Kingdom; BCG = 384 
Bacillus Calmette-Guérin; n = number; CI = confidence interval.   385 
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Table 4: Crude and adjusted ORs for the association of LTBI and years since BCG 386 






LTBI (%)  
Crude OR 
(95% CI) 





No BCG 142/453 (31.4) 1  1  
≤10 - -  -  
11-20 27/160 (16.9) 0.44 (0.28-0.70)  0.55 (0.33-0.90)  
>20 423/1254 (33.7) 1.11 (0.89-1.40) <0.001 0.78 (0.60-1.00) 0.026 
>2 years 
(n=1236) 
No BCG 142/453 (31.4) 1  1  
≤10 12/106 (11.3) 0.28 (0.15-0.53)  0.31 (0.15-0.63)  
11-20 51/243 (21.1) 0.58 (0.40-0.84)  0.73 (0.48-1.10)  
>20 92/434 (21.2) 0.59 (0.43-0.80) <0.001 0.67 (0.46-0.98) 0.0014 
* Likelihood ratio test p value 388 
**Adjusted for age group, sex, ethnicity and country of birth (UK or non-UK) 389 
OR = odds ratio; LTBI = latent tuberculosis infection; BCG = Bacillus Calmette-Guérin; n = 390 
number; CI = confidence interval; UK = United Kingdom.   391 
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Appendix 1: Sensitivity analyses 574 
Sensitivity analyses produced results largely similar to the main analysis (Table A1a). 575 
Adjustment for smoking status and any social risk factor (as proxy measures of 576 
socioeconomic status) gave an OR of 0.67 (0.54-0.84). With adjustment for TB incidence of 577 
country of birth, the OR was 0.69 (0.55-0.87). When the analysis was restricted to 578 
participants with concordant IGRAs, the OR was 0.68 (95% CI 0.51-0.90). Using log 579 
binomial regression yielded a prevalence ration (PR) of 0.80 (95% CI 0.69-0.92). When 580 
participants with prior TB contact were included, the OR increased slightly to 0.73 (95% CI 581 
0.59-0.90) and restricting the analysis to household contacts produced a slightly lower OR of 582 
0.65 (95% CI 0.49-0.87).  583 
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Table A1a: Sensitivity analyses. Adjusted effect estimates for the association between LTBI 584 
and BCG vaccination. 585 
Sensitivity analysis Number Adjusted effect 
estimate* 
95% CI p value** 
Original logistic regression model 3399 OR=0.70 0.56-0.87 0.0017 
Additional adjustment for smoking 
and social risk factors 3384 OR=0.67 0.54-0.84 0.0007 
Additional adjustment for TB 
incidence of country of birth 3390 OR=0.69 0.55-0.87 0.0017 
Restricted to participants with 
concordant IGRAs 2760 OR=0.68 0.51-0.90 0.0088 
Log binomial regression model 3399 PR=0.80 0.69-0.92 0.0031 
Participants with prior contact with 
TB included 3927 OR=0.73 0.59-0.90 0.0033 
Restricted to household contacts 2118 OR=0.65 0.49-0.87 0.0038 
*Adjusted for age group, sex and latitude of country of birth (unless otherwise stated) 586 
**Likelihood ratio test p value  587 
CI = confidence interval; OR = odds ratio; PR = prevalence ratio; IGRA = interferon-gamma 588 
release assay; TB = tuberculosis. 589 
 36 
Table A1b: Analysis of the association of BCG status with tuberculin skin test positivity (n 590 




positive (%)  
Crude OR 
(95% CI) 
p value* Adjusted OR** 
(95% CI) 
p value * 
All 5mm No BCG 160/421 (38.0) 1  1  
BCG 1371/2698 (50.8) 1.69 (1.37-2.08) <0.001 1.59 (1.28-1.98) <0.001 
No BCG 5mm 
BCG 15mm 
No BCG 160/421 (38.0) 1  1  
BCG 695/2698 (25.8) 0.57 (0.46-0.70) <0.001 0.50 (0.40-0.63) <0.001 
*Likelihood ratio test p value 592 
**Adjusted for age group, sex and latitude of country of birth; n = 3072 in the adjusted 593 
analyses. 594 
OR = odds ratio; TST = tuberculin skin test; BCG = Bacillus Calmette-Guérin; CI = 595 
confidence interval; n= number.  596 
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Appendix 2: Missing data analysis 597 
We analysed missing data by outcome and primary exposure, which showed most variables 598 
had very low percentages of missing data (Table A2a). Data on the outcome (LTBI) was 599 
missing in 363 participants (8.4%). There was no association between missing outcome data 600 
and BCG vaccination (OR 1.05, 95% CI 0.74-1.49, p=0.79). Data on BCG vaccination was 601 
missing in 555 participants (12.9%). Those with data missing on BCG status were more 602 
likely to have LTBI (OR 1.33, 95% CI 1.09-1.63). 603 
Multivariable analysis of covariates associated with missing BCG status showed that age 604 
group, country of birth, latitude of country of birth, ethnicity and immunosuppression were 605 
independently associated with missing BCG status (Table A2b). 606 
Although data were missing on the age of vaccination and years since vaccination for a 607 
quarter of subjects, there was no evidence that this was associated with the outcome (LTBI). 608 
Missing data in the primary analysis 609 
There were little missing data on covariates, so the complete-case approach only resulted in a 610 
further 1.6% of participants being excluded from the primary analysis due to missing 611 
covariate data.   612 
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Table A2a: Missingness analysis. Odds ratios of LTBI positivity and BCG vaccination, in 613 
participants missing data on baseline variables versus those with data not missing (n=4310) 614 





95% CI p value** OR of BCG 
vaccination 
(n=3755) 
95% CI p value** 
LTBI 363 (8.42) - - - 1.05 0.74-1.49 0.79 
BCG vaccination 555 (12.88) 1.33 1.09-1.63 0.005 - - - 
Sex 23 (0.53) 0.90 0.32-2.52 0.85 0.80 0.23-2.76 0.73 
Age group, years 7 (0.16) 1.27 0.11-13.99 0.85 0.15 0.009-2.42 0.12 
Country of birth 21 (0.49) 2.91 1.05-8.05 0.03 0.60 0.13-2.84 0.52 
Ethnicity 109 (2.53) 1.46 0.97-2.22 0.07 1.36 0.65-2.85 0.41 
Any social risk factor 0 (0) - - - - - - 
HIV 152 (3.53) 1.00 0.68-1.46 0.99 1.22 0.68-2.19 0.50 
Other 
immunosuppression 16 (0.37) 3.18 0.85-11.86 0.07 0.38 0.07-1.94 0.22 
Diabetes 16 (0.37) 1.44 0.42-4.96 0.55 0.75 0.09-6.45 0.79 
Smoking status 30 (0.70) 0.70 0.26-1.90 0.48 0.30 0.11-0.80 0.01 
Latitude of country of 
birth 58 (1.35) 0.94 0.50-1.78 0.85 0.46 0.22-0.95 0.03 
Age at vaccination 
(if vaccinated, n=3264) 888 (27.21) 0.90 0.75-1.07 0.24 - - - 
Years since BCG 
(if vaccinated, n=3264) 860   (26.35) 0.91 0.76-1.10 0.34 - - - 
Setting of TB exposure 340 (7.89) 0.98 0.76-1.26 0.87 0.536 0.40-0.73 <0.001 
*Number missing out of total (n=4310) 615 
**Derived from chi-squared test  616 
LTBI = latent tuberculosis infection; BCG = Bacillus Calmette-Guérin; n = number; CI = 617 
confidence interval; OR = odds ratio; HIV = human immunodeficiency virus.   618 
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Table A2b: Missingness analysis. Multivariable analysis of the association of covariates with 619 
missing BCG status (n=3657) 620 
Variable Group Adjusted OR* 95% CI p value** 
LTBI  Negative 1   
Positive 1.37 1.10-1.70 0.005 
Sex Male 1   
Female 0.98 0.79-1.20 0.82 
Age group, years 
 
16-25 1   
26-35 0.90 0.69-1.16 0.41 
36-45 0.62 0.44-0.87 0.006 
>45 1.15 0.85-1.56 0.36 
Country of birth UK 1   
Non-UK 1.65 1.05-2.54 0.028 
Ethnicity Indian 1   
White 0.79 0.54-1.16 0.23 
Black African 0.93 0.61-1.40 0.71 
Mixed 1.00 0.71-1.39 0.99 
Pakistani 1.44 0.48-1.00 0.048 
Bangladeshi 1.16 0.70-1.94 0.56 
Black Caribbean 1.09 0.64-1.85 0.74 
Black Other / 
Chinese / Other 
0.66 0.35-1.27 0.22 
Any social risk factor No 1   
Yes 0.97 0.62-1.52 0.90 
HIV No 1   
Yes 0.86 0.25-2.91 0.81 
Other immunosuppression No 1   
Yes 2.12 1.32-3.38 0.002 
Diabetes 
 
No 1   
Yes 1.08 0.72-1.62 0.72 
Smoking status Ever 1   
Never 1.09 0.84-1.42 0.50 
Latitude of country of birth 
 
<20° 1   
20-40° 1.20 0.84-1.72 0.32 
>40° 1.67 0.98-2.86 0.06 
*Adjusted for all other variables in the table  621 
**Wald test p value 622 
BCG = Bacillus Calmette-Guérin; n = number; OR = odds ratio; CI = confidence interval; LTBI = latent 623 
tuberculosis infection; UK = United Kingdom; HIV = human immunodeficiency virus.  624 
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Appendix 3: Analysis of age at BCG by ethnicity and place of birth 625 
Table A3: The distribution of age at BCG by ethnicity, stratified by place of birth (UK born 626 
or non-UK born) 627 
Country of birth Ethnicity 




n (%) n (%) 
 Indian 41 (30) 95 (70) 
 White 41 (16) 216 (84) 
 Black African 11 (26) 31 (74) 
 Mixed 13 (20) 51 (80) 
 Pakistani 14 (36) 25 (64) 
 Bangladeshi 10 (40) 15 (60) 
 Black Caribbean 5 (10) 43 (90) 
 Black other / Chinese / other 8 (35) 15 (65) 
 Missing 1 (14) 6 (86) 
 Total 144 (22) 497 (78) 
      
Non-UK born      
 Indian 415 (84) 82 (17) 
 White 136 (72) 53 (28) 
 Black African 263 (86) 42 (14) 
 Mixed 219 (84) 42 (16) 
 Pakistani 92 (88) 13 (12) 
 Bangladeshi 52 (84) 10 (16) 
 Black Caribbean 32 (58) 23 (42) 
 Black other / Chinese / other 45 (82) 10 (18) 
 Missing 14 (56) 11 (44) 
 Total 1,268 (82) 286 (18) 
BCG = Bacillus Calmette-Guérin; n = number; UK = United Kingdom  628 
